UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute

Breast cancer research and treatment, 2015-11, Vol.154 (1), p.89-97

2015

Volltextzugriff (PDF)

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

Breast cancer research and treatment, 2017-08, Vol.164 (3), p.649-658

2017

Volltextzugriff (PDF)

'Economies of scale' yield multiple benefits for a private, physician-run oncology practice

Oncology (Williston Park, N.Y.), 2013-07, Vol.27 (7), p.616, 618, C3-618

2013

Volltextzugriff (PDF)

Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS7571-TPS7571

2021

Volltextzugriff (PDF)

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7559-7559

2022

Volltextzugriff (PDF)

Self-stated and actual practice patterns of general medical oncologists (MO) regarding the use of predictive biomarkers to guide treatment for patients (pts) with chronic lymphocytic leukemia (CLL)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e19510-e19510

2018

Volltextzugriff (PDF)

General medical oncologists assessment and use of targeted treatment for patients (pts) with metastatic nonsquamous non-small cell lung cancer (nsqNSCLC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e18186-e18186

2017

Volltextzugriff (PDF)

Relationship Between Lenalidomide Dose Modification and Duration Of Treatment In Newly Diagnosed Multiple Myeloma Patients

Blood, 2013-11, Vol.122 (21), p.2944-2944

2013

Volltextzugriff (PDF)

Relationship Between Lenalidomide Dose Modification and Time to Next Treatment in Newly Diagnosed Multiple Myeloma Patients

Blood, 2014-12, Vol.124 (21), p.2655-2655

2014

Volltextzugriff (PDF)

Rate of pathologic fractures associated with zoledronic acid treatment in both breast and prostate cancer patients with bone metastases: Findings from real-world clinical practice

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e19615-e19615

2012

Volltextzugriff (PDF)

Drug resource use and costs for novel agents in multiple myeloma

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e18560-e18560

2012

Volltextzugriff (PDF)

TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.1000-1000

2015

Volltextzugriff (PDF)

A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (n-pac) combined with OGX-427 (apatorsen) or placebo in patients (pts) with metastatic pancreatic cancer (mPaCa): The Rainier Trial

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS4163-TPS4163

2014

Volltextzugriff (PDF)

Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood, 2012-11, Vol.120 (21), p.719-719

2012

Volltextzugriff (PDF)

Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A phase II trial of the Sarah Cannon Research Institute (SCRI)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.1086-1086

2012

Volltextzugriff (PDF)

A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Blood, 2011-11, Vol.118 (21), p.3912-3912

2011

Volltextzugriff (PDF)

Low doses of prophylactic cranial irradiation effective in limited stage small cell carcinoma of the lung

International journal of radiation oncology, biology, physics, 1995-09, Vol.33 (2), p.329-337

1995

Volltextzugriff (PDF)

Interactions between mural cells and endothelial cells stabilize the developing zebrafish dorsal aorta

Development (Cambridge), 2017-01, Vol.144 (1), p.115-127

2017

Volltextzugriff (PDF)

Predicting the outcome of total knee arthroplasty

Journal of bone and joint surgery. American volume, 2004-10, Vol.86 (10), p.2179-2186

2004

Volltextzugriff (PDF)

Mural-Endothelial cell-cell interactions stabilize the developing zebrafish dorsal aorta

Development (Cambridge), 2016-01

2016

Volltextzugriff (PDF)

Knee range of motion after total knee arthroplasty: How important is this as an outcome measure?

The Journal of arthroplasty, 2003-04, Vol.18 (3), p.286-294

2003

Volltextzugriff (PDF)

Hardware retrofit and computed torque control of a PUMA 560 robot: Innovations in Undergraduate Education

IEEE control systems, 2004, Vol.24 (5), p.78-82

2004

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(21)
magazinearticle
(1)

Sprache

Englisch
(22)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

'Economies of scale' yield multiple benefits for a private, physician-run oncology practice

Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress)

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study

Self-stated and actual practice patterns of general medical oncologists (MO) regarding the use of predictive biomarkers to guide treatment for patients (pts) with chronic lymphocytic leukemia (CLL)

General medical oncologists assessment and use of targeted treatment for patients (pts) with metastatic nonsquamous non-small cell lung cancer (nsqNSCLC)

Relationship Between Lenalidomide Dose Modification and Duration Of Treatment In Newly Diagnosed Multiple Myeloma Patients

Relationship Between Lenalidomide Dose Modification and Time to Next Treatment in Newly Diagnosed Multiple Myeloma Patients

Rate of pathologic fractures associated with zoledronic acid treatment in both breast and prostate cancer patients with bone metastases: Findings from real-world clinical practice

Drug resource use and costs for novel agents in multiple myeloma

TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by ixabepilone (Ixa) or paclitaxel (Pac) in early-stage, triple-negative breast cancer (TNBC)

A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (n-pac) combined with OGX-427 (apatorsen) or placebo in patients (pts) with metastatic pancreatic cancer (mPaCa): The Rainier Trial

Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A phase II trial of the Sarah Cannon Research Institute (SCRI)

A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Low doses of prophylactic cranial irradiation effective in limited stage small cell carcinoma of the lung

Interactions between mural cells and endothelial cells stabilize the developing zebrafish dorsal aorta

Predicting the outcome of total knee arthroplasty

Mural-Endothelial cell-cell interactions stabilize the developing zebrafish dorsal aorta

Knee range of motion after total knee arthroplasty: How important is this as an outcome measure?

Hardware retrofit and computed torque control of a PUMA 560 robot: Innovations in Undergraduate Education

Suchergebnisse filtern